FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897038355> ?p ?o ?g. }

• W2897038355 abstract "<h3>Background</h3> Nivolumab is approved for the treatment of refractory metastatic renal cell carcinoma. Patterns and predictors of progressive disease (PD) on nivolumab, and outcomes in such patients are lacking. <h3>Methods</h3> A retrospective analysis of patients (pts) with metastatic clear cell renal cell carcinoma (ccRCC) who received nivolumab at Cleveland Clinic (2015–2017) was performed. PD was defined per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or clinical progression as per treating physician. Univariate analyses (UVA) and multivariate analyses (MVA) were used to identify clinical and laboratory markers as potential predictors of progression-free survival (PFS). <h3>Results</h3> Ninety patients with mean age of 65, 74% men, and 83% good or intermediate International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk group were included. Median number of prior systemic treatments was 2 (range, 1–6). Median overall survival (OS) and PFS were 15.8 and 4.4 months, respectively. Fifty-seven patients (63%) had PD and 44% of patients with radiographic PD had new organ sites of metastases with brain (8/23, 35%) being the most common. Twelve patients received treatment beyond progression (TBP), and among 6 patients with available data, 3 (50%) had any tumor shrinkage (2 pts. with 17% shrinkage, one pt. with 29% shrinkage). Of 57 patients with PD, 28 patients (49%) were able to initiate subsequent treatment, mainly with axitinib and cabozantinib, while 40% of patients were transitioned to hospice after PD. In MVA, a higher baseline Neutrophil-to-Lymphocyte ratio (NLR) (HR, 1.86; 95% CI, 1.05–3.29; <i>p</i> = 0.033) was associated with an increased risk of progression, whereas higher (> 0.1 k/uL) baseline eosinophil count was associated with a lower risk of progression (HR, 0.54; 95% CI, 0.30–0.98; <i>p</i> = 0.042). <h3>Conclusion</h3> Brain was the most common site of PD in patients treated with nivolumab, and only half of patients progressing on nivolumab were able to initiate subsequent treatment. The risk of PD increased with a higher baseline NLR and reduced with a higher baseline eosinophil count." @default.
• W2897038355 created "2018-10-26" @default.
• W2897038355 creator A5002681805 @default.
• W2897038355 creator A5006289336 @default.
• W2897038355 creator A5008174951 @default.
• W2897038355 creator A5024482335 @default.
• W2897038355 creator A5025529463 @default.
• W2897038355 creator A5026717218 @default.
• W2897038355 creator A5031016267 @default.
• W2897038355 creator A5041898186 @default.
• W2897038355 creator A5053588971 @default.
• W2897038355 creator A5056587248 @default.
• W2897038355 creator A5079937462 @default.
• W2897038355 date "2018-10-17" @default.
• W2897038355 modified "2023-10-16" @default.
• W2897038355 title "Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab" @default.
• W2897038355 cites W1967084952 @default.
• W2897038355 cites W1978679603 @default.
• W2897038355 cites W2000756990 @default.
• W2897038355 cites W2018992636 @default.
• W2897038355 cites W2039123767 @default.
• W2897038355 cites W2046434791 @default.
• W2897038355 cites W2073212944 @default.
• W2897038355 cites W2089783760 @default.
• W2897038355 cites W2095176390 @default.
• W2897038355 cites W2099752220 @default.
• W2897038355 cites W2101019048 @default.
• W2897038355 cites W2104885590 @default.
• W2897038355 cites W2107863654 @default.
• W2897038355 cites W2121850852 @default.
• W2897038355 cites W2123914905 @default.
• W2897038355 cites W2128085654 @default.
• W2897038355 cites W2147286476 @default.
• W2897038355 cites W2160834915 @default.
• W2897038355 cites W2222086386 @default.
• W2897038355 cites W2281395530 @default.
• W2897038355 cites W2282962877 @default.
• W2897038355 cites W2470761206 @default.
• W2897038355 cites W2528223683 @default.
• W2897038355 cites W2547310148 @default.
• W2897038355 cites W2560367415 @default.
• W2897038355 cites W2604665500 @default.
• W2897038355 cites W2725398806 @default.
• W2897038355 cites W2762055451 @default.
• W2897038355 cites W2763133656 @default.
• W2897038355 cites W2783295481 @default.
• W2897038355 cites W2789662395 @default.
• W2897038355 cites W2792937256 @default.
• W2897038355 cites W2805302875 @default.
• W2897038355 doi "https://doi.org/10.1186/s40425-018-0425-8" @default.
• W2897038355 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6192175" @default.
• W2897038355 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30333065" @default.
• W2897038355 hasPublicationYear "2018" @default.
• W2897038355 type Work @default.
• W2897038355 sameAs 2897038355 @default.
• W2897038355 citedByCount "52" @default.
• W2897038355 countsByYear W28970383552019 @default.
• W2897038355 countsByYear W28970383552020 @default.
• W2897038355 countsByYear W28970383552021 @default.
• W2897038355 countsByYear W28970383552022 @default.
• W2897038355 countsByYear W28970383552023 @default.
• W2897038355 crossrefType "journal-article" @default.
• W2897038355 hasAuthorship W2897038355A5002681805 @default.
• W2897038355 hasAuthorship W2897038355A5006289336 @default.
• W2897038355 hasAuthorship W2897038355A5008174951 @default.
• W2897038355 hasAuthorship W2897038355A5024482335 @default.
• W2897038355 hasAuthorship W2897038355A5025529463 @default.
• W2897038355 hasAuthorship W2897038355A5026717218 @default.
• W2897038355 hasAuthorship W2897038355A5031016267 @default.
• W2897038355 hasAuthorship W2897038355A5041898186 @default.
• W2897038355 hasAuthorship W2897038355A5053588971 @default.
• W2897038355 hasAuthorship W2897038355A5056587248 @default.
• W2897038355 hasAuthorship W2897038355A5079937462 @default.
• W2897038355 hasBestOaLocation W28970383551 @default.
• W2897038355 hasConcept C121332964 @default.
• W2897038355 hasConcept C121608353 @default.
• W2897038355 hasConcept C126322002 @default.
• W2897038355 hasConcept C142424586 @default.
• W2897038355 hasConcept C143998085 @default.
• W2897038355 hasConcept C144301174 @default.
• W2897038355 hasConcept C2776539811 @default.
• W2897038355 hasConcept C2776694085 @default.
• W2897038355 hasConcept C2776907518 @default.
• W2897038355 hasConcept C2777472916 @default.
• W2897038355 hasConcept C2777701055 @default.
• W2897038355 hasConcept C2778822529 @default.
• W2897038355 hasConcept C2779134260 @default.
• W2897038355 hasConcept C2779490328 @default.
• W2897038355 hasConcept C2779984678 @default.
• W2897038355 hasConcept C2780030458 @default.
• W2897038355 hasConcept C2780739268 @default.
• W2897038355 hasConcept C2781278892 @default.
• W2897038355 hasConcept C38180746 @default.
• W2897038355 hasConcept C71924100 @default.
• W2897038355 hasConcept C87355193 @default.
• W2897038355 hasConceptScore W2897038355C121332964 @default.
• W2897038355 hasConceptScore W2897038355C121608353 @default.
• W2897038355 hasConceptScore W2897038355C126322002 @default.
• W2897038355 hasConceptScore W2897038355C142424586 @default.
• W2897038355 hasConceptScore W2897038355C143998085 @default.

• next